FOSAVANCE

This brand name is authorized in Austria, Canada, Cyprus, Germany, Spain, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug FOSAVANCE contains a combination of these active pharmaceutical ingredients (APIs):

1 Alendronate sodium trihydrate
UNII 2UY4M2U3RA - ALENDRONATE SODIUM

Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.

Read about Alendronic acid
2 Vitamin D3
UNII 1C6V77QF41 - CHOLECALCIFEROL

In its biologically active form vitamin D3 stimulates intestinal calcium absorption, incorporation of calcium into the osteoid, and release of calcium from bone tissue. In the small intestine it promotes rapid and delayed calcium uptake. The passive and active transport of phosphate is also stimulated.

Read about Vitamin D3

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
FOSAVANCE Tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
M05BB03 Alendronic acid and colecalciferol M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BB Bisphosphonates, combinations
Discover more medicines within M05BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02276429, 02314940
Country: DE Bundesinstitut für Arzneimittel und Medizinprodukte Identifier(s): 00968730, 00968747, 03420286, 05703143, 14340745, 15241442, 17531032
Country: EE Ravimiamet Identifier(s): 1213344, 1213355, 1213366, 1213377, 1339130, 1339141, 1339152
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 05310002, 05310002IP, 05310007, 05310007IP, 05310007IP1
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 025306, 112368
Country: FR Base de données publique des médicaments Identifier(s): 63591602, 68300050
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 142406, 161821, 374381, 95239
Country: IE Health Products Regulatory Authority Identifier(s): 26112, 37152, 75212, 75251, 75279, 75315, 75318, 75323, 75333, 75382
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 6305
Country: IT Agenzia del Farmaco Identifier(s): 036845028, 036845079
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1004487, 1004488, 1004806, 1005111, 1028603, 1028604, 1028606, 1028607
Country: NL Z-Index G-Standaard, PRK Identifier(s): 122424, 122432
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100143587, 100309770
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W67694001, W67694002, W67694003, W67694004, W67697001, W67697002, W67697003
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 3443032
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8683280337190, 8683280337206
Country: ZA Health Products Regulatory Authority Identifier(s): 44/3.2/0350, A40/3.2/0259

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.